Loading stock data…
ARS Pharmaceuticals (SPRY)
$8.56+0.02 (+0.23%)
Market ClosedLast close Jun 29
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ARS Pharmaceuticals, Inc. in the Healthcare sector is trading at $8.56 with a market capitalization of $957M. Wall Street consensus targets $29.25 (4 analysts), implying a +241.7% move over the next 12 months. The stock is currently near its 52-week low of $6.66, remaining 8.4% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +241.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $22.68M↓ | $28.09M↓ | $32.50M↑ | $15.72M↑ | $7.97M |
| Gross Profit | $16.39M↓ | $21.93M↓ | $24.31M↑ | $10.73M↑ | $6.88M |
| Operating Income | -$60.15M↓ | -$41.47M↑ | -$53.19M↓ | -$47.61M↓ | -$37.18M |
| Net Income | -$60.62M↓ | -$41.32M↑ | -$51.15M↓ | -$44.88M↓ | -$33.94M |
Peer Comparison
JNJUNHPFE
Fundamentals
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal deliv...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$957.28M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-322.92%
Volume
Today's trading volume
1.41M
Recent News
ARS Pharmaceuticals (SPRY) Is Down 11.5% After Losing Spots in Key Russell 2000 Defensive Indices
In late June 2026, ARS Pharmaceuticals, Inc. (NasdaqGM: SPRY) was removed from both the Russell 2000 Growth-Defensive Index and the Russell 2000 Defensive Index, altering its presence in widely followed small-cap benchmarks. This dual index removal could affect the company’s visibility and index-linked ownership, prompting investors to reassess how they monitor and access ARS Pharmaceuticals’ stock. We’ll now examine how ARS Pharmaceuticals’ removal from key Russell 2000 defensive indices...
ARS Pharma Collapses After CVS Punts Its Epinephrine Spray Decision To January
ARS Pharmaceuticals stock collapsed Thursday after CVS Caremark declined to add its epinephrine spray, Neffy, to its formulary.
Micron Sparks Fresh AI Stock Rally
AI chip rally powers gains as inflation data looms.
SPRY, PASG, BOXL: Why These Stocks Plunged Double Digits In After-Hours Trading Today
The after-hours decline was driven by concerns over trading activity, business performance and company restructuring plans.
SPRY Stock Tanks Over 23% After-Hours — ARS Pharmaceuticals Reports No New Major Insurance Wins For Neffy
Many patients will continue to face higher out-of-pocket costs or rely on the company’s cash-pay option without broader commercial coverage.